Urokinase in rheumatoid arthritis: causal or coincidental?

The past 10 years have witnessed an increased interest in the plasminogen activation system and its potential role(s) in rheumatoid arthritis (RA). Two types of plasminogen activators (PAs), urokinase (uPA) and tissue type PA (tPA), which are structurally, immunologically, and genetically distinct, have been identified in mammals. Both PAs are secreted as a single chain protein, which in the case of uPA is essentially inactive (pro-uPA). Pro-uPA is then converted by a single enzymatic cleavage into two chain active enzyme. uPA and tPA are highly specific serine proteases catalysing the conversion of plasminogen into plasmin.\(^{12}\)

Plasminogen, present in plasma and extracellular fluids, can bind to fibrin and also to cell surface plasminogen receptors (PinR), via its lysine binding sites. The activity of PAs is controlled by natural inhibitors (PAls), which include PAI-1, the main PAI in the circulation, and PAI-2.\(^{6–9}\) Finally, increased uPA and decreased tPA responses,\(^{3–5}\) Increased levels of uPAR, PAI-1, and PAI-2 were observed anomalies in RA synovium. Alternatively, active uPA can generate plasmin, a protease of broad specificity, which can act on numerous substrates within the joint. Plasmin has been shown to activate and mobilise latent forms of growth/angiogenic factors such as transforming growth factor \(\beta\) and scatter factor; both factors are expressed within arthritic joints and believed to have important pathogenic effects. Modulation of uPA mediated proteolytic activity may therefore influence indirectly the growth and differentiation of cellular constituents in arthritic joints, although this role remains to be shown both in vitro and in vivo.

The best reported and probably also the most important substrates of plasmin are extracellular matrix proteins. uPA mediated plasminogen activation seems thus to be involved in two prominent features of RA characterised by extracellular matrix degradation: joint destruction and intra-articular fibrin turnover. Joint damage with cartilage and bone destruction is believed to be mediated mainly through the release of neutral proteases (represented by metalloproteases (MMPs) and plasmin) by activated synovial cells of the pannus, chondrocytes, and inflammatory cells.\(^{11}\) Plasmin may play a pivotal part in this degradative process as it can directly degrade cartilage proteoglycans as well as other cartilage and bone matrix proteins or indirectly, through the activation of latent MMPs. A contribution of uPA to cartilage and bone degradation has been shown in different in vitro experimental models. Degradation of cartilage explants induced by interleukin 1 or tumour necrosis factor \(\alpha\) has been correlated with the induction of uPA activity.\(^{10–11}\)

Degradation of a radiolabelled bone-like matrix was achieved by mouse cells transfected with human uPA, but not by cells transfected with human uPAR; moreover, cocultivation of uPA and uPAR expressing cells resulted in a pronounced increase in matrix degradation.

As an alternative view of the role of uPA in RA, we must consider its role in fibrin degradation. Accumulation of intra-articular fibrin is a common feature of RA, occurring on the synovial membrane, on the cartilage surface, and as
particular aggregates (the typical ‘rice bodies’) in synovial fluid. These fibrin deposits are the results of the intra-articular balance between coagulation and fibrinolysis. Increased expression of tissue factor and factor XIII by articular endothelial cells and macrophages have been reported, thus providing the ability to generate and cross link fibrin in RA synovial tissues. Degradation of fibrin matrix is performed by plasmin. The most tangible evidence of ongoing fibrinolysis is the generation of fibrin degradation products such as cross linked, plasmin modified fibrin (fibrin d-dimer). The presence of fibrin d-dimer was confirmed, using specific antibodies, in RA synovium. Although the role of uPA in intra-articular fibrin removal has not been assessed in vivo, the concomitant presence of fibrin d-dimer and increased uPA activity in RA synovial tissues, suggests ongoing uPA mediated fibrinolysis in RA joints. Interestingly, in other inflammatory situations, such as septic shock and lung injury, a correlation between extravascular fibrin deposition and decreased uPA activity has been found, supporting uPA as a crucial enzyme in extravascular fibrin clearance.

Intra-articular fibrin deposits can have potential adverse effects. The presence of fibrin on synovium and cartilage may impede normal nutrition to these tissues, thus amplifying conditions that lead to hypoxia and acidosis in synovial fluid, as suggested by Harris. Fibrin(ogen) degradation products may also have direct proinflammatory effects by increasing vascular permeability and inducing chemotaxis at sites of inflammation. Fibrin(ogen) also serves as a provisional matrix for inflammation. This potential arthritic role of fibrin in RA is supported by studies in animals where homologous fibrin injected intra-articularly in previously immunised rabbits induced a chronic inflammatory arthritis. The proinflammatory role of fibrin(ogen) in human joints has also been reported: a proportion of patients treated with silicon rubber joint prostheses developed synovial and osseous inflammation, probably mediated by the spontaneous adsorption of fibrinogen on the implanted polymer surfaces.

uPA mediated proteolytic activity in RA has already been considered as a target for therapeutic intervention in this disease. It has been hypothesised that compounds inhibiting uPA mediated activity could represent new pharmacological tools to reduce joint destruction. Indeed, clinical improvement of arthritic patients was seen after intra-articular injection of urinary trypsin inhibitor, which was shown to inhibit uPA. In this context, the finding that glucocorticosteroids suppress uPA activity of human synovial cells, chondrocytes, and mononuclear cells could represent one of the mechanisms leading to the beneficial effects of these anti-inflammatory drugs in the treatment of RA. On the other hand, as discussed above, intra-articular fibrin may be highly detrimental in RA. Thus, agents able to decrease extravascular fibrin deposition might ameliorate RA synovitis. Belch et al. noted that the anabolic androgenic steroid stanozolol increased plasma fibrinolytic activity and improved inflammation in RA patients. It was postulated that the improvement may be attributable to a reduction in synovial fibrin, mediated by the increased fibrinolytic activity.

Variations in uPA activity levels could occur during the course of the disease and within the joint, favouring one or another feature of RA. The relative importance of the contrasting roles of uPA in RA pathogenesis (deleterious with respect to joint destruction, beneficial in the context of fibrin mediated inflammation) needs to be assessed in vivo. The availability of animals genetically deficient in uPA offers us the means to clarify the uPA role(s) in arthritis. Ultimately, elucidation of the in vivo role of uPA in arthriti-
Urokinase in rheumatoid arthritis: causal or coincidental?

NATHALIE BUSSO and ALEXANDER SO

doi: 10.1136/ard.56.12.705

Updated information and services can be found at:
http://ard.bmj.com/content/56/12/705

These include:

References
This article cites 25 articles, 10 of which you can access for free at:
http://ard.bmj.com/content/56/12/705#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Osteoarthritis (931)
- Pathology (444)
- Clinical diagnostic tests (1282)
- Radiology (1113)
- Surgical diagnostic tests (431)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/